IL133680A0 - Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist - Google Patents

Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Info

Publication number
IL133680A0
IL133680A0 IL13368099A IL13368099A IL133680A0 IL 133680 A0 IL133680 A0 IL 133680A0 IL 13368099 A IL13368099 A IL 13368099A IL 13368099 A IL13368099 A IL 13368099A IL 133680 A0 IL133680 A0 IL 133680A0
Authority
IL
Israel
Prior art keywords
antagonist
pharmaceutical compositions
receptor agonist
adenosine receptor
adenosine
Prior art date
Application number
IL13368099A
Other languages
English (en)
Original Assignee
Can Fite Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13186499A external-priority patent/IL131864A0/xx
Application filed by Can Fite Technologies Ltd filed Critical Can Fite Technologies Ltd
Priority to IL13368099A priority Critical patent/IL133680A0/xx
Priority to KR1020067006473A priority patent/KR100674529B1/ko
Priority to HU0203870A priority patent/HU226913B1/hu
Priority to CA002384111A priority patent/CA2384111C/en
Priority to JP2001522994A priority patent/JP4980530B2/ja
Priority to MXPA02002546A priority patent/MXPA02002546A/es
Priority to RU2002109228/15A priority patent/RU2239455C2/ru
Priority to EP00956773A priority patent/EP1261322B1/en
Priority to PL356469A priority patent/PL199852B1/pl
Priority to KR1020027003164A priority patent/KR100584797B1/ko
Priority to PT00956773T priority patent/PT1261322E/pt
Priority to CNB008148007A priority patent/CN100358512C/zh
Priority to PCT/IL2000/000550 priority patent/WO2001019360A2/en
Priority to US09/700,751 priority patent/US7064112B1/en
Priority to AU68634/00A priority patent/AU782826B2/en
Priority to DE60037277T priority patent/DE60037277T2/de
Priority to DK00956773T priority patent/DK1261322T3/da
Priority to BR0013905-0A priority patent/BR0013905A/pt
Priority to ES00956773T priority patent/ES2296637T3/es
Publication of IL133680A0 publication Critical patent/IL133680A0/xx
Priority to HK03105018.4A priority patent/HK1052653B/zh
Priority to US11/286,376 priority patent/US20060084626A1/en
Priority to JP2007128137A priority patent/JP2007204496A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL13368099A 1999-09-10 1999-12-23 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist IL133680A0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IL13368099A IL133680A0 (en) 1999-09-10 1999-12-23 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
ES00956773T ES2296637T3 (es) 1999-09-10 2000-09-08 Composiciones farmaceuticas que contienen un antagonista o un agonista del receptor de adenosina.
PT00956773T PT1261322E (pt) 1999-09-10 2000-09-08 Composições farmacêuticas compreendendo um agonista ou antagonista do receptor de adenosina
PCT/IL2000/000550 WO2001019360A2 (en) 1999-09-10 2000-09-08 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CA002384111A CA2384111C (en) 1999-09-10 2000-09-08 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP2001522994A JP4980530B2 (ja) 1999-09-10 2000-09-08 アデノシン受容体アゴニストまたはアンタゴニストを含む製薬組成物
MXPA02002546A MXPA02002546A (es) 1999-09-10 2000-09-08 Composiciones farmaceuticas que comprenden un receptor agonista o antagonista de la adenosina.
RU2002109228/15A RU2239455C2 (ru) 1999-09-10 2000-09-08 Фармацевтические композиции, содержащие агонист или антагонист аденозинового рецептора
EP00956773A EP1261322B1 (en) 1999-09-10 2000-09-08 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
PL356469A PL199852B1 (pl) 1999-09-10 2000-09-08 Zastosowanie skutecznej ilości agonisty receptora adenozynowego A3
KR1020027003164A KR100584797B1 (ko) 1999-09-10 2000-09-08 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물
KR1020067006473A KR100674529B1 (ko) 1999-09-10 2000-09-08 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물
CNB008148007A CN100358512C (zh) 1999-09-10 2000-09-08 包含腺苷受体激动剂或拮抗剂的药物组合物
HU0203870A HU226913B1 (en) 1999-09-10 2000-09-08 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US09/700,751 US7064112B1 (en) 1999-09-10 2000-09-08 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU68634/00A AU782826B2 (en) 1999-09-10 2000-09-08 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
DE60037277T DE60037277T2 (de) 1999-09-10 2000-09-08 Adenosinrezeptor-agonist oder antagonist enthaltende pharmazeutische zusammensetzungen
DK00956773T DK1261322T3 (da) 1999-09-10 2000-09-08 Farmaceutiske sammensætninger omfattende en adenosinreceptoragonist eller antagonist
BR0013905-0A BR0013905A (pt) 1999-09-10 2000-09-08 Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag
HK03105018.4A HK1052653B (zh) 1999-09-10 2003-07-11 包含腺苷受體激動劑或拮抗劑的藥物組合物
US11/286,376 US20060084626A1 (en) 1999-09-10 2005-11-25 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP2007128137A JP2007204496A (ja) 1999-09-10 2007-05-14 アデノシン受容体アゴニストまたはアンタゴニストを含む製薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13186499A IL131864A0 (en) 1999-09-10 1999-09-10 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
IL13368099A IL133680A0 (en) 1999-09-10 1999-12-23 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Publications (1)

Publication Number Publication Date
IL133680A0 true IL133680A0 (en) 2001-04-30

Family

ID=26323880

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13368099A IL133680A0 (en) 1999-09-10 1999-12-23 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Country Status (19)

Country Link
US (2) US7064112B1 (xx)
EP (1) EP1261322B1 (xx)
JP (2) JP4980530B2 (xx)
KR (2) KR100674529B1 (xx)
CN (1) CN100358512C (xx)
AU (1) AU782826B2 (xx)
BR (1) BR0013905A (xx)
CA (1) CA2384111C (xx)
DE (1) DE60037277T2 (xx)
DK (1) DK1261322T3 (xx)
ES (1) ES2296637T3 (xx)
HK (1) HK1052653B (xx)
HU (1) HU226913B1 (xx)
IL (1) IL133680A0 (xx)
MX (1) MXPA02002546A (xx)
PL (1) PL199852B1 (xx)
PT (1) PT1261322E (xx)
RU (1) RU2239455C2 (xx)
WO (1) WO2001019360A2 (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
CN1234358C (zh) * 2000-06-21 2006-01-04 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物
AU2002219497B2 (en) * 2001-01-16 2004-08-26 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US20040204481A1 (en) * 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US7049303B2 (en) * 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US20040137477A1 (en) * 2002-10-22 2004-07-15 Can-Fite Biopharma, Ltd. A3AR as a marker for a diseased state
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
EA011279B1 (ru) 2004-05-24 2009-02-27 Ф. Хоффманн-Ля Рош Аг (4-метокси-7-морфолин-4-илбензотиазол-2-ил)-амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты
KR101167342B1 (ko) 2004-05-26 2012-07-19 이노텍 파마슈티컬스 코포레이션 아데노신 ａ1 수용체 아고니스트로서의 퓨린 유도체 및 이것의 사용 방법
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
AU2005286946B2 (en) 2004-09-20 2012-03-15 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
JP4633123B2 (ja) 2004-11-05 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー イソニコチン酸誘導体の製造方法
MX2007005525A (es) * 2004-11-08 2007-07-05 Can Fite Biopharma Ltd Tratamiento terapeutico de resorcion ose acelerada.
JP2008520746A (ja) * 2004-11-22 2008-06-19 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療
KR100968989B1 (ko) 2005-03-23 2010-07-09 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘 유도체
CN101273040B (zh) 2005-09-27 2011-11-09 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物
AU2006320578B2 (en) 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
CN101365430B (zh) * 2006-01-27 2011-09-21 坎-菲特生物药物有限公司 用于治疗干眼病的腺苷a3受体激动剂
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
JP2010505848A (ja) * 2006-10-06 2010-02-25 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア 眼内圧を低下させるための種交差性ａ３アデノシン受容体アンタゴニストの効果的送達
GB0625100D0 (en) * 2006-12-15 2007-01-24 Univ Murcia Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
TW200914048A (en) * 2007-07-17 2009-04-01 Combinatorx Inc Combinations for the treatment of B-cell proliferative disorders
US20090053168A1 (en) * 2007-07-17 2009-02-26 Richard Rickles Treatments of b-cell proliferative disorders
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2010027935A1 (en) 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
CA2761499A1 (en) 2009-05-17 2010-11-25 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US20120322815A1 (en) * 2009-12-17 2012-12-20 Ewha University-Industry Collaboration Foundation Pharmaceutical composition containing a3 adenosine receptor agonist
WO2011085361A1 (en) 2010-01-11 2011-07-14 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
CA2790869A1 (en) 2010-03-03 2011-09-09 Government Of The Usa, Represented By The Secretary, Department Of Healt H And Human Services A3ar agonists for the treatment of uveitis
US8476247B2 (en) 2010-03-26 2013-07-02 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans
US20130109645A1 (en) * 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
UY34536A (es) 2011-12-22 2013-07-31 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
WO2013111132A1 (en) * 2012-01-23 2013-08-01 Can-Fite Biopharma Ltd. Treatment of liver conditions
AU2013211957B2 (en) 2012-01-26 2017-08-10 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of (2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
CN105358551A (zh) 2012-07-19 2016-02-24 詹森药业有限公司 Ccr2的八氢环戊并吡咯基拮抗剂
MX2015001644A (es) 2012-08-09 2015-08-14 Can Fite Biopharma Ltd Ligandos del receptor de adenosina a3 para su uso en el tratamiento de una disfuncion sexual.
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
WO2017185061A1 (en) 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
JP7311855B2 (ja) 2018-02-09 2023-07-20 アストロサイト ファーマシューティカルズ， インコーポレイテッド 嗜癖および関連する障害を処置するための化合物および方法
CN112930349A (zh) 2018-09-26 2021-06-08 阿斯特罗赛特制药公司 多晶形化合物及其用途
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU7331094A (en) 1993-07-13 1995-02-13 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor agonists
GB2289218A (en) * 1994-05-06 1995-11-15 Merck & Co Inc Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor
RU2071770C1 (ru) 1994-12-14 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака шейки матки и яичников
RU2071771C1 (ru) 1995-01-11 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака молочной железы
US6211165B1 (en) * 1997-05-09 2001-04-03 The Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
EP1019427A4 (en) * 1997-07-29 2000-07-19 Medco Res Inc N? 6 -SUBSTITUES-ADENOSINE-5'-URONAMIDES USEFUL AS MODULATORS OF ADENOSINE RECEPTORS
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
US6329349B1 (en) 1997-10-23 2001-12-11 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
CA2316994A1 (en) * 1998-06-08 1999-12-16 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
IL127947A0 (en) * 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
UA72912C2 (uk) * 1999-02-01 2005-05-16 Юніверсіті Оф Вірджінія Патент Фаундейшн Композиція для лікування запальної реакції
IL131096A (en) 1999-07-26 2004-09-27 Can Fite Technologies Ltd Method for preparing a composition derived from muscle tissue

Also Published As

Publication number Publication date
HU226913B1 (en) 2010-03-01
ES2296637T3 (es) 2008-05-01
KR100584797B1 (ko) 2006-06-02
HK1052653B (zh) 2008-08-01
CA2384111A1 (en) 2001-03-22
DK1261322T3 (da) 2008-04-07
WO2001019360A2 (en) 2001-03-22
US7064112B1 (en) 2006-06-20
KR20060036490A (ko) 2006-04-28
JP2007204496A (ja) 2007-08-16
RU2239455C2 (ru) 2004-11-10
JP4980530B2 (ja) 2012-07-18
KR100674529B1 (ko) 2007-01-30
KR20020038749A (ko) 2002-05-23
DE60037277D1 (de) 2008-01-10
HUP0203870A2 (hu) 2003-03-28
DE60037277T2 (de) 2008-10-09
CN100358512C (zh) 2008-01-02
CA2384111C (en) 2008-05-27
PL199852B1 (pl) 2008-11-28
PT1261322E (pt) 2008-01-09
AU782826B2 (en) 2005-09-01
HK1052653A1 (en) 2003-09-26
CN1391468A (zh) 2003-01-15
EP1261322A2 (en) 2002-12-04
JP2003514771A (ja) 2003-04-22
MXPA02002546A (es) 2003-07-21
BR0013905A (pt) 2003-07-15
WO2001019360A3 (en) 2002-09-19
AU6863400A (en) 2001-04-17
RU2002109228A (ru) 2004-01-10
US20060084626A1 (en) 2006-04-20
EP1261322B1 (en) 2007-11-28
PL356469A1 (en) 2004-06-28
HUP0203870A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
HUP0203870A3 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
HUP0203638A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use
HUP0201545A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them
HK1059575A1 (en) Nmda receptor agonist pharmaceutical compositions
HUP0401437A3 (en) Adenosine a3 receptor agonists
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
IS5706A (is) Adenosín A3 viðtakastillar
EP1187614A4 (en) SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
HK1049007B (zh) 腺苷a2a受體拮抗劑
IL142958A0 (en) Vitronectin receptor antagonist pharmaceuticals
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
IL160715A0 (en) Pharmaceutical compositions containing an a1 adenosine receptor antagonist
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
EG24025A (en) Vitronectin receptor antagonist
HUP0203603A3 (en) Novel il-8 receptor antagonist indole derivatives and pharmaceutical compositions containing them
AU4980999A (en) A3 adenosine receptor antagonists
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
HUP0200057A3 (en) Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
IL131864A0 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU2002302774A1 (en) Macrophage receptor agonist or antagonist
SI1347760T1 (en) Nmda receptor agonist pharmaceutical compositions
IL165716A0 (en) Pharmaceutical compositions containing heterocyclic adenosine receptor antagonists
HU0800727D0 (hu) Opioid agonista és antagonista hatóanyagot tartalmazó gyógyszerkészítmény
GB0015901D0 (en) Compositions containing 5ht receptor agonists

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
EXP Patent expired